Company intelligence / Profile preview

SK Group

Seoul/Pangyo, Seoul/Gyeonggi, South Koreaeng.sk.com ↗

Ownership: Private
Employees: ~117000
Development stage: Commercial

Overview

SK Biopharmaceuticals/SK Life Science have independently developed cenobamate for epilepsy—FDA approved and commercialized in the US. Solriamfetol was discovered by the company and outlicensed. The group is expanding into oncology and advanced therapeutic modalities with ongoing clinical trials globally.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeRadiopharmaceuticalCell therapyGene therapy
Industry: Biotech

Drug pipeline

2 assets

cenobamate

Commercial

Indications: Epilepsy, Partial-onset seizures

1 more asset in the full pipeline.

Request access →

Partnerships

Outlicensing partnerships for solriamfetolglobal collaborations via CDMO business through SK Pharmteco

Beyond the preview

Go deeper on SK Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK Group.

Explore the full profile